Aims

To support the free and open dissemination of research findings and information on alcoholism and alcohol-related problems. To encourage open access to peer-reviewed articles free for all to view.

For full versions of posted research articles readers are encouraged to email requests for "electronic reprints" (text file, PDF files, FAX copies) to the corresponding or lead author, who is highlighted in the posting.

___________________________________________

Thursday, February 22, 2007

Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO)

This study is currently recruiting patients.
Verified by Hospital University Vall d'Hebron February 2007

Sponsored by: Hospital University Vall d'Hebron
Information provided by: Hospital University Vall d'Hebron
ClinicalTrials.gov Identifier: NCT00437177

Purpose

OH dependence is associated with DA receptor changes. Both, the apomorphine test and the D2Rec SPECt are usefull for monitoring DA receptor status. We aimed at studying whether DA receptor hypofunction, assessed by means of the apomorphine test and the D2Rec SPECT, is a marker of relapse in detoxified OH dependents patients.
Condition Intervention Phase
Alcoholism
 Drug: apomorphine
Drug: [(123)I] iodobenzamide
 Phase II

MedlinePlus related topics: Alcoholism

Study Type: Interventional
Study Design: Non-Randomized, Open Label, Uncontrolled, Single Group Assignment

Official Title: Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence: Predictive Value for Relapse

Further study details as provided by Hospital University Vall d'Hebron:

Expected Total Enrollment: 50

Study start: January 2007
Last follow-up: January 2007

Eligibility

Ages Eligible for Study: 25 Years - 60 Years, Genders Eligible for Study: Male
Criteria

Inclusion Criteria:

  • alcohol dependence
  • alcohol dependence length at least 8 years.
  • male
  • age 25 - 60 years

Exclusion Criteria:

  • other drug dependence (except nicotine dependence)
  • another major axis I psychiatric diagnosis
  • comorbid neurological disorder
  • comorbid cardiovascular disorder
  • comorbid metabolic disorder
  • brain injury
  • apomorphine allergy
  • iode allergy
  • diazepam allergy

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier NCT00437177
Xavier Castells, MD xcc@icf.uab.cat
Miquel Casas, Prof mcasas@vhebron.net

Spain, Catalonia
Psychiatry Service, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, 08036, Spain; Recruiting
Xavier Castells, MD xcc@icf.uab.cat
Miquel Casas mcasas@vhebron.net
Miquel Casas, Prof, Principal Investigator

Study chairs or principal investigators

Miquel Casas, Prof, Principal Investigator, Psychiatry Service, Hospital Universitari Vall d'Hebron

More Information

Study ID Numbers: OH SPECT APO; EudraCT: 2004-001893-24
Last Updated: February 17, 2007
Record first received: February 16, 2007
ClinicalTrials.gov Identifier: NCT00437177
Health Authority: Spain: Spanish Agency of Medicines
ClinicalTrials.gov processed this record on 2007-02-22
at